Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
Launched by VA SALT LAKE CITY HEALTH CARE SYSTEM · Apr 4, 2012
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
Chlordiazepoxide 25 mg and matching placebo capsules or gabapentin 300 mg and matching placebo capsules were were used. The chlordiazepoxide/placebo and gabapentin/placebo capsules were not identical in appearance. Study medications were packaged into a 7-day medication organizer. The dosing for each subject was either gabapentin 1200mg or chlordiazepoxide 100 mg orally days 1-3, gabapentin 900 mg or chlordiazepoxide 75 mg day 4, gabapentin 600 mg or chlordiazepoxide 50 mg day 5, and gabapentin 300 mg or chlordiazepoxide 25 mg day 6.
Adherence was assessed by pill counts and serum samples ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Alcohol dependent at risk for withdrawal symptoms
- Exclusion Criteria:
- • Benzodiazepine dependent
About Va Salt Lake City Health Care System
The VA Salt Lake City Health Care System (VASLCHCS) is a leading healthcare provider dedicated to serving veterans through comprehensive medical services and innovative research initiatives. As a prominent clinical trial sponsor, VASLCHCS leverages its extensive expertise and resources to advance medical knowledge and improve patient outcomes. With a commitment to excellence in both clinical care and research, the organization fosters collaborations aimed at developing novel therapies and enhancing treatment protocols, ultimately striving to enhance the quality of life for veterans and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Christopher J Stock, PharmD
Principal Investigator
Salt Lake VA Health Care System
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials